title: Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Porifera and Coelenterata.
abstract: An ever increasing demand for new lead compounds in the pharmaceutical industry has led scientists to search for natural bioactive products. Based on this extensive research, marine invertebrates now represent a rich source of novel substances with significant anti-neoplastic activities. As the current approach of synthesizing new and chemically modifying old drugs seems to have slowed down, and the identification of new anticancer drugs is not too promising, a new approach is clearly needed. The objective of this review is to present up-to-date data on these newer compounds. Based on the data summarized in this short review, it is clear that marine invertebrates represent an extremely important source of compounds with potential anti-cancer effects. Considering that we tested only a tiny number of Porifera and Coelenterata, the best is yet to come.
authors.affiliation: Peter Sima, Institute of Microbiology, Czech Academy of Sciences, 142 20 Prague 15400, Czech Republic.
authors.forename: Peter
authors.initials: P
authors.lastname: Sima
authors.forename: Vaclav
authors.initials: V
authors.lastname: Vetvicka
references.citation: Br J Cancer. 2001 Sep 1;85(5):741-6
references.pmid: 11531261
references.citation: Folia Microbiol (Praha). 2003;48(2):123-37
references.pmid: 12800493
references.citation: Mar Drugs. 2011;9(6):944-951
references.pmid: 21747740
references.citation: J Nat Prod. 2007 Mar;70(3):412-6
references.pmid: 17309301
references.citation: Curr Med Chem Anticancer Agents. 2005 Jan;5(1):65-71
references.pmid: 15720262
references.citation: Phytochem Rev. 2009 Jun;8(2):415-429
references.pmid: 20622986
references.citation: Cancer Chemother Pharmacol. 1999;44(2):131-7
references.pmid: 10412947
references.citation: J Nat Prod. 1989 Nov-Dec;52(6):1189-208
references.pmid: 2693613
references.citation: Angew Chem Int Ed Engl. 1998 Sep 4;37(16):2162-2178
references.pmid: 29711453
references.citation: Bioorg Med Chem Lett. 2007 Jan 15;17(2):346-9
references.pmid: 17095216
references.citation: Org Lett. 2008 Dec 4;10(23):5465-8
references.pmid: 18975955
references.citation: Ann Oncol. 2003 Nov;14(11):1607-15
references.pmid: 14581267
references.citation: Mar Drugs. 2010 Feb 23;8(2):313-46
references.pmid: 20390108
references.citation: J Nat Prod. 2007 Mar;70(3):423-4
references.pmid: 17378531
references.citation: Bioessays. 1997 Sep;19(9):777-86
references.pmid: 9297968
references.citation: Mar Biotechnol (NY). 2005 May-Jun;7(3):142-62
references.pmid: 15776313
references.citation: J Nat Prod. 2004 Dec;67(12):2033-6
references.pmid: 15620246
references.citation: J Nat Prod. 2000 Dec;63(12):1686-8
references.pmid: 11141118
references.citation: Curr Med Chem. 2006;13(17):2041-90
references.pmid: 16842196
references.citation: Nat Prod Commun. 2009 Dec;4(12):1717-28
references.pmid: 20120114
references.citation: Toxicon. 1994 Jun;32(6):639-55
references.pmid: 7940572
references.citation: Biochem Pharmacol. 1991 Jul 25;42(4):745-51
references.pmid: 1867631
references.citation: Angew Chem Int Ed Engl. 2007;46(48):9211-4
references.pmid: 18022886
references.citation: J Nat Prod. 2001 Dec;64(12):1489-92
references.pmid: 11754596
references.citation: Nat Prod Commun. 2009 Feb;4(2):185-92
references.pmid: 19370920
references.citation: Lancet Infect Dis. 2003 Jun;3(6):338-48
references.pmid: 12781505
references.citation: Curr Drug Targets. 2006 Mar;7(3):265-77
references.pmid: 16515527
references.citation: Curr Pharm Biotechnol. 2009 Jan;10(1):86-105
references.pmid: 19149592
references.citation: Cancer Res. 1998 Mar 15;58(6):1111-5
references.pmid: 9515790
references.citation: Mar Drugs. 2010 Mar 31;8(4):1059-79
references.pmid: 20479967
references.citation: Mar Drugs. 2009 Dec 23;7(4):833-49
references.pmid: 20098613
references.citation: Int J Cancer. 2003 Jun 20;105(3):291-9
references.pmid: 12704660
references.citation: Nat Rev Drug Discov. 2009 Jan;8(1):69-85
references.pmid: 19096380
references.citation: Mar Drugs. 2010 Mar 01;8(3):438-59
references.pmid: 20411108
references.citation: J Nat Prod. 2009 Mar 27;72(3):507-15
references.pmid: 19125622
references.citation: Mol Cell Biol. 1992 Dec;12(12):5447-54
references.pmid: 1448077
references.citation: Arch Pharm Res. 2006 Feb;29(2):131-4
references.pmid: 16526276
references.citation: Prog Mol Subcell Biol. 2009;46:1-44
references.pmid: 19184583
references.citation: Mol Cancer Ther. 2008 Mar;7(3):548-58
references.pmid: 18347142
references.citation: Curr Top Microbiol Immunol. 2000;248:67-107
references.pmid: 10793475
references.citation: Biochemistry. 1999 Apr 27;38(17):5490-8
references.pmid: 10220336
references.citation: J Nat Prod. 1998 Aug;61(8):1022-4
references.pmid: 9722490
references.citation: Anticancer Drugs. 2002 May;13 Suppl 1:S15-9
references.pmid: 12173490
references.citation: Nat Prod Rep. 2009 Feb;26(2):170-244
references.pmid: 19177222
references.citation: Prog Mol Subcell Biol. 2009;46:187-219
references.pmid: 19184589